Testosterone Therapy in Castrate-Resistant Prostate Cancer: A Possible New Approach

European Urology

Volumn 56, Issue 2, 2009, Pages 245-246

  Gardiner, Robert A ^a   Sweeney, Christopher ^b   Tilley, Wayne D ^c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; TESTOSTERONE;

ANDROGEN DEPRIVATION THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER RISK; CARDIOTOXICITY; CASTRATION; CLINICAL TRIAL; DRUG EFFICACY; DRUG INHIBITION; DRUG SAFETY; DRUG WITHDRAWAL; EDITORIAL; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER;

DRUG RESISTANCE, NEOPLASM; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM METASTASIS; ORCHIECTOMY; PROSTATIC NEOPLASMS; TESTOSTERONE; TREATMENT FAILURE;

EID: 67649449945     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2009.04.030     Document Type: Editorial

References (10)

1. Scher H.I., Buchanan G., Gerald W., Butler L.M., and Tilley W.D. Targeting the androgen receptor: improving outcomes for castration resistant prostate cancer. Endocr Relat Cancer 11 (2004) 459-476
2. Mohler J.L. Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 617 (2008) 223-234
3. Attard G., Reid A.H.M., Yap T.A., et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26 (2008) 4563-4571
4. Morris M.J., Huang D., Kelly W.K., et al. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 56 (2009) 237-244
5. Kokontis J.M., Hay N., and Liao S. Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest. Mol Endocrinol 12 (1998) 941-953
6. Umekita Y., Hiipakka R.A., Kokontis J.M., and Liao S. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci U S A 93 (1996) 11802-11807
7. Manni A., Bartholomew M., Caplan R., et al. Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome. J Clin Oncol 6 (1988) 1456-1466
8. Szmulewitz R., Mohile S., Posadas E., et al. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 56 (2009) 97-104
9. Dehdashti F., Picus J., Michalski J.M., et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 32 (2005) 344-350
10. Leversha M.A., Han J., Asgari Z., et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 15 (2009) 2091-2097